Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin formation. Dextrose 5% provides caloric support.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
IV: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr; adjust based on aPTT. Typical concentration: 20,000 units heparin in 500 mL D5W (40 units/mL).
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
30–150 minutes (mean 90 min) for continuous IV infusion; shorter with higher doses due to saturable clearance. Prolonged in hepatic or renal impairment.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Renal: negligible at therapeutic doses; hepatic metabolism to uroheparin and low molecular weight species; biliary/fecal: minimal. Clearance is dose-dependent and saturable.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category A/B
Category C
Anticoagulant
Anticoagulant